The coagulopathy in patients with coronavirus disease 2019 (COVID-19) from infection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus—especially in hospitalized settings and in the immediate post-hospital discharge period—has been well-described. Based on early data from observational studies, multiple high-quality randomized controlled trials have been conducted worldwide to evaluate optimal antithrombotic regimens with anticoagulants and antiplatelet agents in both outpatient and hospitalized settings to reduce the risk of death, venous and arterial thromboembolism, escalation of therapy, and other related adverse outcomes in COVID-19 patients. In addition, best practices have advocated for optimal management of COVID-19-associated thromboembolic disease, usually in hospitalized settings. These efforts have led to formalized antithrombotic guideline recommendations for the prevention and treatment of COVID-19-associated coagulopathy, both in non-hospitalized and hospitalized settings.